FALCO HOLDINGS Co., Ltd AI Stock Analysis
Want to see JP:4671 full AI Analyst Report?
FALCO HOLDINGS Co., Ltd (4671) AI Stock Analysis
FALCO HOLDINGS Co., Ltd
(TSE/TYO:4671)
The stock scores 72, reflecting a solid financial foundation with a strong balance sheet and healthy cash flows, offset by some margin pressure. The technical picture shows a bullish trend but is overbought, suggesting caution in the short term. Valuation appears attractive with a reasonable P/E and high dividend yield. Overall, the company is well-positioned in the Medical Diagnostics & Research industry.
FALCO HOLDINGS Co., Ltd (4671) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 26.96B
- Dividend Yield
- 4.63%
- Average Volume (3M)
- 18.29K
- Price to Earnings (P/E)
- 12.6
- Beta (1Y)
- 0.53
- Revenue Growth
- 1.19%
- EPS Growth
- 16.02%
- Country
- Japan
- Employees
- 1,037
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
FALCO HOLDINGS Co., Ltd Business Overview & Revenue Model
Company Description
FALCO HOLDINGS Co., Ltd., a medical services enterprise established in 1962 and headquartered in Kyoto, Japan, primarily delivers clinical diagnostic testing and pharmaceutical dispensing solutions. The company serves medical institutions and various...
How the Company Makes Money
FALCO HOLDINGS generates revenue mainly by providing clinical laboratory testing services to healthcare providers. In this model, medical institutions (e.g., clinics and hospitals) send patient specimens to the company’s laboratories for analysis; th...
FALCO HOLDINGS Co., Ltd Financial Statement Overview
Summary
Revenue growth rebounded (12.6% latest year) and gross margins improved, but operating margin declined indicating expense pressure. Balance sheet is strong with low debt (debt-to-equity 0.05) and growing equity. Cash flow generation is healthy. Overall solid but with some income statement weakness.
Income Statement
58NeutralBalance Sheet
85Very PositiveCash Flow
72Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.10B | 43.58B | 43.31B | 43.01B | 46.91B | 50.01B |
| Gross Profit | 14.29B | 13.81B | 13.35B | 12.92B | 14.64B | 17.32B |
| EBITDA | 4.02B | 3.56B | 3.72B | 3.56B | 4.75B | 6.55B |
| Net Income | 2.17B | 2.02B | 1.92B | 1.67B | 2.26B | 3.53B |
Balance Sheet | ||||||
| Total Assets | 37.04B | 36.86B | 36.02B | 36.42B | 38.89B | 40.26B |
| Cash, Cash Equivalents and Short-Term Investments | 9.25B | 9.27B | 9.42B | 10.06B | 12.60B | 10.64B |
| Total Debt | 939.00M | 1.25B | 1.44B | 817.00M | 2.80B | 4.07B |
| Total Liabilities | 11.25B | 10.99B | 10.76B | 10.40B | 12.30B | 16.77B |
| Stockholders Equity | 25.79B | 25.87B | 25.25B | 26.03B | 26.59B | 23.48B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.54B | 1.54B | 2.19B | 708.00M | 1.94B |
| Operating Cash Flow | 0 | 2.88B | 2.62B | 3.43B | 2.09B | 4.13B |
| Investing Cash Flow | 0 | -2.03B | -1.18B | -1.45B | 322.00M | -2.69B |
| Financing Cash Flow | 0 | -2.00B | -2.08B | -4.53B | -448.00M | -2.41B |
FALCO HOLDINGS Co., Ltd Peers Comparison
Overall Rating
JP:467172Outperform
JP:469470Outperform
JP:453864Neutral
JP:457964Neutral
JP:239559Neutral
JP:456342Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | JPY 26.84B | 12.56 | ― | 4.63% | 1.19% | 16.02% | |
| 70Outperform | JPY 148.09B | 19.51 | 5.92% | 3.22% | 3.54% | 10.43% | |
| 64Neutral | JPY 19.31B | 8.49 | ― | 4.09% | 2.29% | ― | |
| 64Neutral | JPY 16.82B | 44.72 | ― | ― | 31.84% | ― | |
| 59Neutral | JPY 51.58B | 8.90 | ― | 4.04% | 1.89% | 22.53% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 42Neutral | JPY 11.13B | -1.91 | -558.92% | ― | 19.67% | 84.06% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4671 | FALCO HOLDINGS Co., Ltd | 2731.00 | 301.66 | 12.42% | |
| JP:4563 | AnGes | 27.00 | -47.00 | -63.51% | |
| JP:4694 | BML | 3960.00 | 417.96 | 11.80% | |
| JP:2395 | Shin Nippon Biomedical Laboratories, Ltd. | 1239.00 | -324.11 | -20.73% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2201.00 | 128.93 | 6.22% | |
| JP:4579 | RaQualia Pharma Inc. | 646.00 | 83.00 | 14.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026
